Results 201 to 210 of about 125,716 (297)

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

open access: yesThe Lancet, 2015
B. Neuschwander‐Tetri   +17 more
semanticscholar   +1 more source

Hepatic fibrosis in patients diagnosed with rheumatoid arthritis and psoriatic arthritis receiving methotrexate: A cross‐sectional analysis using transient elastography

open access: yesRheumatology &Autoimmunity, EarlyView.
Hepatic fibrosis and metabolic syndrome are more prevalent in PsA patients treated with methotrexate, compared to RA patients. Metabolic syndrome is associated with the risk of hepatic fibrosis in patients diagnosed with PsA and RA even after adjustment forcumulative methotrexate exposure.
Ratchaya Lertnawapan   +3 more
wiley   +1 more source

Obstructive sleep apnea and cardiovascular disease in individuals with metabolic dysfunction‐associated fatty liver disease: A prospective cohort study

open access: yesSleep Research, EarlyView.
Abstract Objective To assess the association between obstructive sleep apnea (OSA) risk levels and major cardiovascular disease (CVD) subtypes in individuals with metabolic dysfunction‐associated fatty liver disease (MAFLD). Methods This cohort study included 128,022 MAFLD participants from the UK Biobank without CVD at baseline.
Haizhen Chen   +4 more
wiley   +1 more source

Metabolic dysfunction-associated steatohepatitis is the leading indication for adult liver transplantation in Saudi Arabia. [PDF]

open access: yesPLoS One
Alqahtani SA   +7 more
europepmc   +1 more source

Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids.

open access: yesCell Metabolism, 2019
Rie Ouchi   +22 more
semanticscholar   +1 more source

Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia

open access: yesJournal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy